"These findings suggest that while PCSK9 inhibitors are safe and effective at lowering lipids, their impact on early vascular ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

It cannot be denied that statins have revolutionized how we treat and prevent coronary heart disease. But there are both external and intrinsic reasons why some patients do not respond adequately to ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...

When compared to published data with inclisiran, a small interfering RNA (siRNA) molecule that inhibits production of the PCSK9 enzyme, the data showed lipid lowering for LDL-C, non-HDL-C, ApoB, and ...

PCSK9 inhibitor therapy is less likely to be utilized in Black, Hispanic, and low-income patients hospitalized with ...

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...